Mechanistic target of rapamycin (mTOR)

Overview

The mechanistic target of rapamycin kinase (mTOR) is a central serine/threonine kinase that integrates growth factor, nutrient, energy, and stress signals to regulate cell growth, metabolism, protein synthesis, autophagy, and survival. It is a core component of the PI3K/AKT/mTOR pathway, and its activity is tightly linked to cellular adaptation in both normal physiology and disease. Because of this broad regulatory role, mTOR is a major biomedical target in oncology, inflammatory disease, metabolic disorders, neurodegeneration, and tissue repair.

Pharmacologically, mTOR is best known as the target of sirolimus and everolimus, which suppress mTOR signaling and are used in several clinical settings. In recent research, mTOR has also been studied in connection with AMPK/mTOR, PI3K/AKT, mTOR-TFEB, and related autophagy and lysosomal pathways, reflecting its role as a signaling hub that can either promote anabolic growth or restrain autophagy depending on cellular context.

Recent Publications Summary

Recent publications continued to position mechanistic target of rapamycin (mTOR) as a central signaling node in cancer, cardiovascular disease, neurodegeneration, metabolic injury, and regenerative medicine. In oncology, a randomized phase 2 trial in diffuse intrinsic pontine glioma compared radiotherapy plus everolimus with other targeted agents and found no overall survival advantage for the biomarker-guided treatment arms over the control cohort 42032072Apr. In pancreatic neuroendocrine tumors, integrative RNA-splicing analysis identified a subgroup with enhanced mTOR signaling, underscoring its association with clinically relevant tumor heterogeneity 42424015Jul. Additional cancer-focused work described an in silico pipeline that identified feline-specific mTOR-binding compounds for hypertrophic cardiomyopathy, with dihydro-alpha-ergocryptine showing stronger predicted binding and stability than rapamycin 42371166Jun. A separate study developed a SIN1-targeting inhibitor intended to disrupt mTORC2 and rapamycin-sensitive mTORC1 signaling, suppress downstream MAPK signaling, and inhibit proliferation across multiple cancer cell lines 41423418Dec.

Several studies linked mTOR to autophagy and mitochondrial quality control. In heart failure with preserved ejection fraction, urolithin A activated AMPK while inhibiting mTOR, promoting ULK1-dependent autophagy initiation and restoring impaired mitophagic flux, with accompanying improvements in cardiac remodeling and mitochondrial function in mice 42432192Jul. In osteoporosis, betulinic acid alleviated inflammatory injury in osteoblasts by augmenting autophagy through the AMPK-mTOR pathway 42138188May. In spinal cord injury, platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes promoted nerve regeneration and reduced neuronal apoptosis and autophagy via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis 42165939May. In pancreatic ductal adenocarcinoma, irinotecan-induced resistance was associated with a temporal pattern in which early AMPK-driven autophagy was followed by later mTOR activation, yet autophagy and fatty acid oxidation persisted; inhibiting fatty acid oxidation disrupted this survival program 42008004Apr. In Friedreich’s ataxia, cardiac mitochondrial iron overload was associated with lysosomal dysfunction and impaired mitophagy, with accumulation of p62 and Parkin proteins, placing defective mitochondrial clearance in the context of disease-related cardiac hypertrophy 41628678Feb.

mTOR also appeared in studies of metabolic, inflammatory, and neurological disease. In diabetic neuropathy, chronic hyperglycemia was associated with impaired autophagic flux alongside mTOR activation and AMPK inhibition, suggesting that dysregulated mTOR signaling contributes to neuronal dysfunction 42424320Jul. In Alzheimer’s disease-related blood-brain barrier models, butyrate was investigated for its effects on amyloid-β transport and endothelial accumulation through insulin signaling pathways, with mTOR included among the signaling mechanisms under evaluation 42166642May. A review of neuroinflammation and neurodegeneration highlighted mTOR and AMPK as key regulators of autophagy dysfunction and inflammatory injury, and discussed mTOR inhibitors as potential therapeutic strategies 41918200Apr. Another review on intermittent fasting similarly emphasized AMPK- and SIRT1-linked autophagy regulation in brain aging, with mTOR implied as part of the broader nutrient-sensing network 41811567Mar.

Beyond disease-specific studies, recent publications also discussed mTOR in broader translational contexts. A protocol for a systematic review of metformin for pain noted that metformin may exert analgesic effects through AMPK activation and downstream inhibition of mTOR and MAPK signaling 42468965Jul. In HIV research, transcriptomic analysis of CD4+ T cells from antiretroviral therapy interruption cohorts identified the mTOR inhibitor DDIT4 as associated with delayed viral rebound, and metformin induced DDIT4 while suppressing HIV expression in primary cells and cells from people with HIV 41864210Mar. In atherosclerosis, a review of ubiquitin-specific proteases described USP14 as promoting disease through activation of mTOR signaling in smooth muscle cells 41747799Feb. In cardiac xenotransplantation, sirolimus and related mTOR suppressors were proposed as tools to mitigate “missing self” rejection and cardiac hypertrophy in xenografts 41909987Mar.

What Changes, What Holds

1. mTOR remains a broadly relevant cancer target, but the new oncology data mostly refine rather than overturn its role
REINFORCES The recent cancer studies keep mTOR in the same central position described in the Overview: a signaling hub implicated across tumor types and still therapeutically actionable, yet not uniformly predictive of benefit. The negative randomized result in diffuse intrinsic pontine glioma 42032072Apr argues against assuming biomarker-guided mTOR-pathway targeting will translate into survival gain in every setting, while the other findings mainly extend the range of tumor contexts in which mTOR signaling is observed 42424015Jul41423418Dec.

2. New work strengthens the view that mTOR-linked autophagy control is a major disease mechanism, not just a downstream marker
REINFORCES These studies fit the established account that mTOR sits at the center of autophagy and survival programs, but they sharpen the point that disease phenotypes can depend on whether mTOR is suppressing or permitting autophagic flux. The cardiac, bone, spinal cord, and pancreatic findings all use the same core logic: altering AMPK-mTOR balance changes mitochondrial quality control, cell survival, or treatment resistance 42432192Jul42138188May. The Friedreich’s ataxia report adds disease-specific evidence of defective mitochondrial clearance 41628678Feb.

3. mTOR dysregulation now looks more tightly tied to inflammatory and neurologic injury states than the baseline explicitly stated
NEW DIRECTION The Overview already places mTOR in neurodegeneration and metabolic disease, but these papers extend that role into specific injury and barrier contexts, including diabetic neuropathy and Alzheimer’s disease-related blood-brain barrier models 42424320Jul42166642May. They suggest that abnormal mTOR activity is not merely associated with chronic degeneration; it may participate in acute or tissue-specific dysfunction through impaired autophagic flux and insulin-linked signaling. The reviews on neuroinflammation and fasting mainly reinforce that broader nutrient-sensing framework 41918200Apr41811567Mar.

4. mTOR inhibition is being explored as a mechanistic lever across nontraditional translational settings, but these uses remain hypothesis-generating
NEW DIRECTION The new HIV, pain, atherosclerosis, and xenotransplantation papers do not contradict the Overview; instead, they broaden the range of proposed applications beyond the established oncology, inflammatory, metabolic, and repair settings. What changes is the practical framing: mTOR is being treated as a modifiable node in viral rebound, analgesia, vascular disease, and graft rejection, not only as a canonical growth regulator 41864210Mar42468965Jul. These are early translational signals, so they do not yet justify updating the core clinical role of mTOR itself.

Overview update candidates: none.